Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Mumbai: Patient group...

    Mumbai: Patient group opposes hepatitis C drug patent in India

    Written by Ruby Khatun Khatun Published On 2018-07-12T17:58:41+05:30  |  Updated On 12 July 2018 5:58 PM IST
    Mumbai: Patient group opposes hepatitis C drug patent in India

    MUMBAI: 2 hepatitis drugs of Gilead Sciences have drawn the attention of patient group over its patent. A patient advocacy and support group called Delhi Network of Positive People (DNP+) has challenged the additional patent claims by Gilead Sciences for its 2 hepatitis C drugs before the Mumbai Patent Office.


    TOI reports that DNP+ wants to prevent the firm from obtaining patent rights on sofosbuvir and velpatasvir, in order to stop the firm to continue charging exorbitant prices from countries across the world.


    According to the statement of medical humanitarian organisation, Médecins Sans Frontières (MSF), the patent applications of the fixed-dose combination of sofosbuvir/velpatasvir and the polymorph form of velpatasvir has been challended by Delhi Network of Positive People (DNP+).


    It has been reported that the challenge is based on provisions in the Indian Patents Act that prevent patent ‘evergreening’ — which restricts the patentability of a host of secondary patents, i.e., new forms of known substances, new property or new use of known substances, use of known processes without showing any enhanced therapeutic efficacy, and admixtures without synergistic effect.


    In 2016, Gilead Sciences launched sofosbuvir/velpatasvir in the US at over $74,000 for a 12-week regimen.


    Paul Lhungdim of DNP+ told TOI, “Just like Gilead attempted to patent different forms and combinations of the key HIV drug tenofovir many years back, the corporation is again using evergreening tactics to block affordable options of hep C drugs that other countries can import in the future. With these patent challenges, we hope to prevent Gilead from obtaining unmerited patent rights on sofosbuvir and velpatasvir, which would allow them to continue charging exorbitant prices from governments in many middle- and high-income countries.”


    The daily reports that Initiative for Medicines, Access & Knowledge (I-MAK), along with the DNP+, had challenged the basic patent claims on sofosbuvir in 2013 through pre-grant oppositions which is remains under dispute before the Delhi high court and Intellectual Property Appellate Board.


    The basic patent claim on velpatasvir, asserting that the drug is an obvious structural change to an earlier hepatitis C drug ledipasvir, and thus, cannot be patented had been also challenged by I-MAK and DNP+ in February 2017 for which the decision is awaited.


    Indian patent law allows third parties, including civil society organizations to file ‘pre-grant’ oppositions to challenge patent applications until the patent is rejected or granted by the Indian Patent Office.


    Quoting a note, TOI reports that such ‘evergreening’ tactics allow the company to extend their control over the market, in turn delaying the introduction of affordable generic drugs and patient access to treatment in a number of countries.

    Delhi high courtDelhi Network of Positive PeopleDNP+Gilead Scienceshepatitis C drugI-MAKIndian patent lawIntellectual Property Appellate BoardMédecins Sans FrontièresMSFMumbai Patent OfficepatentpatentsPatient groupsofosbuvirVelpatasvir
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok